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Human monocyteIt remains unclear whether antibody-dependent-enhancement (ADE) of dengue infection merely augments
viral attachment and entry through Fcγ receptors or immune complex binding to Fcγ receptors triggers an
intrinsic signaling cascade that changes the viral permissiveness of the cell. Using human dengue–immune
sera and novel humanmonoclonal antibodies against dengue in combination with virologic and immunologic
techniques, we found that ADE infection increased the proportion of infected primary human monocytes
modestly from 0.2%±0.1% (no Ab) to 1.7%±1.6% (with Ab) but the total virus output markedly from 2±2
(×103)FFU to 120±153 (×103)FFU. However, this increased virus production was not associated with a
reduced secretion of type I interferon or an elevated secretion of anti-inﬂammatory cytokine, IL-10. These
results demonstrate that the regulation of virus production in ADE infection of primary human monocytes is
more complex than previously appreciated.Infectious Diseases Division
89, Room 3-5103, Rochester,
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Cross-reactive antibodies or neutralizing antibodies at sub-optimal
concentrations are hypothesized to enhance dengue virus (DENV)
infection during secondary infection with a heterotypic DENV
serotype. This antibody-dependent-enhancement (ADE) of infection
is thought to play an important role in the pathogenesis of dengue
hemorrhagic fever and dengue shock syndrome (DHF/DSS). ADE is
believed to occur through the formation of immune complexes that
bind to Fcγ receptors (FcγRs) on cells such as monocytes/macro-
phages, thus facilitating dengue viral entry and replication, hence
increasing pathogenicity (Halstead, 1981, 1988). Previous studies
have indicated that dengue virus envelop (E) protein domain
speciﬁcity determines whether an antibody neutralizes or enhances
the viral infection (Crill and Roehrig, 2001). Domain speciﬁcity
determines the accessibility of epitopes and therefore the fractional
occupancy that is sufﬁcient for neutralization (Pierson et al., 2008).Recent data also suggest that human antibodies to dengue prM
protein are more potent enhancing antibodies than those that are
speciﬁc for E protein (Dejnirattisai et al., 2010).
How ADE increases virus production is not entirely understood.Many
have suggested that dengue virus–antibody immune complexes infection
results in a greater number of infected cells and hence more virus
production; thus, ADE essentially alters the tropism of the virus. Recent
studies, however, have argued that dengue infection via FcγR-mediated
pathway results in increased synthesis of the anti-inﬂammatory cytokine
IL-10 and suppression of the activity of antiviral type I interferon
(Chareonsirisuthigul et al., 2007; Ubol et al., 2010). This implies that
some cell-intrinsic mechanisms are in operation to augment virus
production in dengue-infected cells, hence the notion of “intrinsic ADE
hypothesis.” These studies, however, were performed on monocytic
leukemia cells, THP-1, that are notably different from primary human
monocytes in terms of permissiveness to dengue virus infection in the
absence of enhancing antibodies and the range of Fcγ receptor surface
expression (Jin et al., 2009). Whether an “intrinsic ADE” mechanism
applies to DENV infection of primary human monocytes/macrophages,
which are the principal dengue target cells in vitro and possibly in vivo
(Blackley et al., 2007; Jessie et al., 2004; Kliks et al., 1989; Kou et al., 2008),
is not known.
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dengue ADE infection, we quantiﬁed virus production in dengue-infected
primary human monocytes with or without enhancing antibodies and
characterized the time course of cytokine production in association with
virus replication kinetics. Our results suggest that ADE infection increased
total viral output without suppressing type I interferon secretion.
Results
Previously, we found that ADE infection increased dengue virus
output by 67-fold (from 413 to 27,500 FFU/ml) whereas the proportion
of infected macrophages only increased 3-fold (from 0.44% to 1.47%) in
comparison to direct DENV infection of human spleen macrophages
in vitro (Blackley et al., 2007). These results imply that virus production
per infected cell is also increased underADE infection, thus leading to an
increase in the average number of infectious virions produced by each
infected cell. In the current study, we performed quantiﬁcation of DENV
infection in primary human monocytes obtained from a larger number
of subjects and examined some intrinsic factors that may affect virus
production per cell (burst size).
ADE infection increased viral infectivity and viral production per cell
The possibility of an increase in burst size with ADE infection was
tested in 16dengue-naïve subjects, and results are summarized in Fig. 1.
PBMC were infected in the presence or absence of pooled human sera
(PHS), and the number of viral infected cells and total virus production
were assessed by FACS and plaque assays, respectively. Results show
that, 48 hours after infection under previously determined conditions of
peak ADE (1/104 or 1/105 dilution of PHS) (Kou et al., 2008), infected
monocytes increased from 0.2%±0.1% (no Ab) to 1.7%±1.6% (with Ab)
(pb0.001) (Fig. 1a) and the total virus output in the supernatants
increased from 2±2 (×103)FFU to 120±153 (×103)FFU (pb0.01)
(Fig. 1b). Mock infection showed background levels of anti-E positivity
that were similar to our previous study (Kou et al., 2008), and no virus
production (Fig. 1a and b). There was a 6 (±4)-fold increase in infected
cells but a striking 67 (±89)-fold increase in the total output of
infectious virus (pb0.01) (Fig. 1c). This translates into an increase in the
virus production per cell from approximately 5 FFU/cell (no Ab) to
36 FFU/cell (in the presence of enhancing Ab). Thus, ADE infection not
only increased the number of infected cells (viral infectivity) but alsoFig. 1. DENV ADE infection with polyclonal human sera increased viral production in prim
infected by DENV2-16681 at an MOI of 5 in the presence (ADE) or absence (Virus) of high
harvested and stained with anti-E antibody 7E1 and analyzed using ﬂow cytometry as descri
are shown (a). Culture supernatants from each infection were harvested and used to infect V
as described in the Materials and methods (b). The fold change in the proportion of infected
from FACS assay and plaque assay and presented (c). FACS assays were performed once foraugmented the amount of infectious virus produced by each infected
cell and together resulted in a greater increase in total virus production.
All previous studies of dengue ADE infection only used polyclonal
human sera or monoclonal murine antibodies, but recently, human
monoclonal antibodies (mAbs) speciﬁc for DENV have become available
for laboratory investigations (Beltramello et al., 2010). We used a unique
set of 4 mAbs against dengue (all IgG1) to further investigate the
phenomenon of viral burst size increase under conditions of ADE
infection. These antibodies were chosen because two of them (DV21.8
and DVC1.6) are E domain III speciﬁc and two others (DVC23.13 and
DVC35.3) are not, and two of the antibodies are speciﬁc for DENV2 only
(DVC1.6 and DVC35.3), while two others (DVC21.8 and DVC23.13) are
cross-reactive to all four dengue serotypes (Beltramello et al., 2010).
Notably, both DIII-speciﬁc monoclonal antibodies enhanced viral infec-
tivity (Fig. 2a) and total virus output (Fig. 2b) at speciﬁc regions of their
dose response curves, despite one of them is cross-reactive to DENV1 to 4
(DVC21.8), and the other only recognizes DENV2 (DVC1.6). Similarly, the
two mAbs that mapped outside of DIII (DVC23.13, cross-reactive with
DENV1–4andDVC35.3, speciﬁc forDENV2) also increasedviral infectivity
(Fig. 2c) and total virus output (Fig. 2d) at speciﬁc regions of their dose
response curves. Although thesemAbsneutralizeddengueviruses inVero
cells, at the concentrations currently used, theywere unable to neutralize
dengue viral infection in PBMC.
Increased infectivity alone cannot account for elevated virus production
in ADE infection
To examine whether increased viral infectivity alone can account for
elevated total viral output in ADE infection, we next performed direct
immunoﬂuorescence microscopy as described in the Materials and
methods. Results conﬁrmed that ADE infection only modestly increased
the percentage of cells infected as observed by FACS. Fig. 3 shows ADE
infection only resulted in a two-fold increase in viral infectivity (from
4.74% to 9.01%) but a six-fold elevation in virus output in culture
supernatants (from 1.9×104 to 12×104 FFU/ml) in comparison to direct
infection by DENV2 (Fig. 3b and c). Therefore, each infected cell made
more infectious virions under ADE infection than direct infection. To
ascertain whether re-infection within the 48 hour assay period poses a
problem for data interpretation, we performed immunoﬂuorescence
microscopy at 6 hours when re-infection is unlikely to have occurred.
Results show a similar proportion of infected cells under direct and ADE
infection conditions (4.9% vs. 5.1%), suggesting again that increased viralary human monocytes. In 16 healthy, dengue-naïve subjects, PBMC were isolated and
ly diluted pooled human sera or mock-infected (Mock). Two days later, the cells were
bed in the Materials and methods. The proportions of infected monocytes in each group
ero cells for three days, and virus production was quantiﬁed using a focus forming assay
cells (Anti-E %) and virus output (Virus FFU) were calculated based on results obtained
each subject; plaque assays were performed in duplicate for each subject.
Fig. 2. Humanmonoclonal antibodies to dengue virus envelope increased viral production in primary human monocytes. The assay set up is as described in Fig. 1 using PBMC from a
dengue-naïve subject, except that serial dilutions of monoclonal antibodies were used. The changes in infected cell percentage (a and c) and total virus production (b and d) in the
presence of DIII-speciﬁc antibodies (DVC21.8 and DVC1.6) (a and b) and non-DIII antibodies (DVC23.13 and DVC35.3) (c and d) were presented. Each graph represents the results of
one experiment.
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virus production in ADE infection, and a burse size increase may offer
another plausible explanation.
Dengue direct and ADE infections do not suppress type I interferon
secretion
What mechanism explains the increased viral burst size observed
in ADE infection? One mechanism is that virus–antibody immuneFig. 3.Modest increase in thenumberof dengue-infected cells underADE infection. Immunoﬂuore
ormock-infected (a) at 48 hours after infection. Cellswere stainedwithanti-E antibody7E1 (green
At least 200 cells in two ﬁelds of view were counted for each condition.complexes infect more cells and result in more virus production.
Alternatively, some intrinsic factors may regulate virus production
per cell. Among intrinsic factors, antiviral type I IFNs, IFNα/β, are
elicited in patients with dengue fever, in DENV-infected human
mononuclear cells in vitro, as well as in volunteers who have received
candidate dengue vaccines in vivo (Chaturvedi et al., 1999; Green
et al., 1999c; Kurane et al., 1993; Libraty et al., 2002; Sanchez et al.,
2006; Ubol et al., 2008). If IFNα/β responses were suppressed and/or
delayed during ADE infection, dengue viral replicationmight increase.scencemicroscopy images of PBMCs infectedunderdirect (b) orADE infection (c) conditions,
) andDAPI (blue). Values shownare averagepercentages of anti-E antibody7E1positive cells.
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ADE infection suppresses type I interferon activity (Ubol et al., 2010),
although in these studies it was difﬁcult to assess whether this was
due to the higher level of infection or enhancement via antibodies and
FcγR signaling. To evaluate this mechanism in primary human
mononuclear cells, direct and ADE infections were performed in
PBMCs from four dengue-naïve donors, and cells and supernatants
were harvested at baseline and then daily for 5 days. As expected,
mock-infected control cells made no virus or IFN (Fig. 4a and d). In
contrast, a high level of dengue virus production was observed at day
2 after infection under both direct and ADE infections (Fig. 4b and c).
Moreover, both dengue direct and ADE infections induced enough IFN
in the cell culture supernatants to achieve signiﬁcant VSV inhibition as
early as 2 days post-infection. There was a wide variability in IFN
production by PBMCs from these four individuals after direct DENV2
infection despite comparable levels of virus production (Fig. 4b and e).
This would suggest that, while viral replication can trigger type
I interferon secretion, it is not the only factor that regulates type I
interferon levels.
Unexpectedly, complete VSV inhibition was achieved in dengue ADE
infection atday2andmaintaineduntil day5 (Fig. 4c and f). It is interesting
tonote that, onday5ofADE infection, the amount of virus productionhad
markedly declined while the VSV inhibition was still 100% (Fig. 4c and f),
indicating there were sufﬁcient amounts of type I interferon in the
supernatants of these cell cultures. These type I interferons may have
come from (1) the stimulation of cells by the very few infectious viruses
that were still being produced, (2) the stimulation of cells by a large
number of non-infectious viral particles that were being made, and
(3) type I interferon carried over from previous days. In an unpublished
work, we found that 100% of VSV inhibition could be achieved with the
exogenous addition of 200 pg/ml of recombinant IFNβ or 500 pg/ml of
recombinant IFNα. Furthermore, the kinetic patterns of interferon
secretion observed in Fig. 4 were also conﬁrmed by ELISA (data not
shown).Fig. 4. Temporal association between viral replication and IFNα/β secretion in DENV-infecte
with dengue virus (DENV2, b and e) or infection with virus pre-incubated with highly dilute
over time and plaque assay was used to determine virus titer (a–c), and the VSV bioassay was
as box-and-whisker plots summarizing data from four healthy dengue-naïve subjects.Delayed IL-10 secretion in both DENV direct and ADE infections of
human PBMCs
Besides type I IFNs, many other cytokine/chemokines that are
normally undetectable in the blood of healthy individuals are
signiﬁcantly elevated in dengue-infected patients, including IL-1β,
IL-2, IL-6, IL-8, IL-10, IL-13, IL-18, IFNγ, TNF-α, and MCP1 (Gagnon
et al., 2002; Green et al., 1999a; Hober et al., 1993; Juffrie et al., 2000;
Kurane et al., 1991; Lee et al., 2006; Mustafa et al., 2001; Nguyen et al.,
2004; Raghupathy et al., 1998). In particular, IL-10 has been suggested
to suppress type I IFN-mediated antiviral activity (Ubol et al., 2010),
whereas TNF-α and IL-8 are independently correlated with dengue
disease severity in humans (Green et al., 1999b; Raghupathy et al.,
1998). We therefore performed a detailed kinetic survey of these and
other inﬂammatory cytokines (IL-6, IL-1β, IL-12) using a cytokine
bead array assay as described in the Materials and methods.
Fig. 5 summarizes results of cytokine secretion over time in PBMCs
obtained from four dengue-naïve donors following mock, DENV2, or
ADE infections. High levels of TNF-α were detected in the culture
supernatants of mock-infected cells on day 5, while only moderate
levels of TNF-αwere detected in direct and ADE infections, suggesting
that normal activation and differentiation of monocytes may be
inhibited in the presence of DENV or dengue–antibody immune
complexes (Fig. 5a). IL-10 secretion increased slightly on day 3 in both
direct and ADE infections (Fig. 5b) when virus production has passed
peak levels (Fig. 4b and c). Statistical analyses found no signiﬁcant
difference in IL-10 and TNF-α secretion at any time point among the
three experimental conditions (p≥0.05). IL-8 levels were high
throughout the 5 day culture period even in the absence of infection,
and slight reduction in IL-8 secretion observed in both direct and ADE
infections in comparison to mock-infected controls was not signiﬁ-
cant (Fig. 5f). The levels of IL-1β and IL-12p70were at their thresholds
of detection (Fig. 5c and d). The changes in IL-6 did not bear any
correlation with the experimental conditions (Fig. 5e).d human PBMC. Freshly isolated PBMCs were infected at an MOI of 5 by direct infection
d PHS (ADE, c and f), or mock-infected (a and d). Culture supernatants were harvested
used to determine interferon activity in the supernatants (d–f). Results were expressed
Fig. 5. Cytokine secretion patterns in DENV infection of human PBMC. Freshly isolated PBMCs were infected at anMOI of 5 by direct infection with dengue virus (DENV2) or infection
with virus pre-incubated with highly diluted PHS (ADE), or mock-infected (Mock). Supernatants were harvested from infected or control cells at 6 hours and 1, 2, 3, and 5 days post-
infection and analyzed for TNF-α (a), IL-10 (b), IL-1β (c), IL-12p70 (d), IL-6 (e), and IL-8 (f) using the CBA assay as described in the Materials and methods. Results (in picogram per
milliliter) were expressed as the mean and standard deviation from four healthy dengue-naïve subjects.
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Secondary dengue infections tend to correlate with higher viremia
levels and more severe disease. The mechanisms for which are
unclear. In this study, we demonstrated that dengue ADE infection, in
comparison to direct DENV infection, increases both the number of
infected primary humanmonocytes and virus production per infected
cell, thereby suggesting a second pathway by which ADE infection
enhances total virus production. To our knowledge, this is the ﬁrst
paper that quantiﬁes enhancement of dengue viral infectivity in
primary human monocytes using both human monoclonal and
polyclonal antibodies. Because primary human monocytes are
believed to be the principal dengue target cells and contribute to
ADE infection in vitro and possibly in vivo (Jessie et al., 2004; Kliks
et al., 1989; Kou et al., 2008), our results may be more relevant for
understanding human dengue disease. Furthermore, in this study, we
demonstrated that human monoclonal antibodies targeting distinct
epitopes on E protein can enhance dengue virus infection.
Our results indicate that the number of infectious virions produced by
each dengue-infected cell was small (5 FFU/cell in direct infection and
36 FFU/cell in ADE infection). This observation is consistent with other
studies in which the amount of infectious virions produced by each
infected cell was estimated, albeit not directlymeasured. In baby hamster
kidney (BHK) cells, peak virus productionwas reached at ~3000 genomic
copies/cell at day 3 after infection with DENV2-16681, which equals
approximately 30–300 FFU/cell in that assay system (Wang et al., 2002).
In human monocyte-derived macrophages, peak virus production was
reached at ~50,000 genomic copies/cell at day 2 after infection with
DENV2-16681, which equals approximately 50 pfu/cell in that experi-
mental system (Cologna and Rico-Hesse, 2003). Because both BHK cells
and humanmacrophages are known to bemore permissive than primary
monocytes to DENV infection, it would be reasonable to expect that each
infectedmonocyteproduces fewervirionswhen inoculatedwith thesame
exact virus (DENV2-16681), just as we have observed.
Our results also imply that, in addition to modulating virus output
by increasing viral infectivity, ADE infection might modulate
intracellular elements that inﬂuence viral production per cells. The
“intrinsic ADE hypothesis” postulates that a depressed antiviral
activity and an upregulation of IL-10 downstream of FcγR-mediated
entry contribute to the observed burst size increase (Ubol et al., 2010).
Although this hypothesis is supported by some experiments with
DENV infection in monocytic cell lines (Chareonsirisuthigul et al.,
2007; Ubol et al., 2010) and with Ross River virus or Leishmania
where IL-10 secretion is hastened or augmented by signaling through
FcγR that resulted in increased pathogenesis (Mahalingam and
Lidbury, 2002; Miles et al., 2005), we did not observe a signiﬁcant
increase in IL-10 or decrease in type I IFN secretion in ADE infection of
primary human monocytes. In fact, IFNα/β secretion was induced
early by direct dengue infection and to a greater magnitude by ADE
infection. These results are consistent with another published study in
which ADE infection of monocytes had no effect on IL-10 secretion
(Boonnak et al., 2008).
Thus, in our study with primary human monocytes that are
believed to be the principal dengue target cells (Jessie et al., 2004;
Kliks et al., 1989; Kou et al., 2008), ADE infection neither suppressed
IFNα/β production nor augmented IL-10 secretion. Moreover, IFNα/β
secretionwas induced early and at a larger quantity by ADE infections.
In contrast, the slight elevation of IL-10 secretion only appeared on
day 3 when active viral replication had greatly reduced and thus was
too late to counter the early IFNα/β-mediated antiviral activity. These
results suggest that enhanced viral infectivity and virus production by
ADE infection are not simply the result of reduced production of
antiviral type I interferons and increased secretion of suppressive
factors such as IL-10, at least not in primary human monocytes.
Given that we did not observe “intrinsic ADE,” we put forward an
alternative idea that, under ADE conditions, Fcγ receptor-bearing cellsuptake higher levels of virus including both free and immune-
complexed viruses, resulting in greater levels of viral replication and
higher virus titers. Further investigations are being conducted to test
whether this is indeed the case.
Materials and methods
Cell lines and DENV
Vero cells (African green monkey kidney epithelial cell line) were
grown in Dulbecco's modiﬁed Eagle's medium, supplemented with 5%
heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2.0 mML-glutamine (DMEM-5) (GIBCO, Invitrogen,
Carlsbad, CA). Experiments in this study used a cell-passaged isolate
of DENV2-16681, which was originally isolated from a fatal case of
DHF/DSS (SB, 1970) (provided by Dr. Richard Kinney, CDC, Fort
Collins, CO). Virus was propagated in C6/36 Aedes albopictusmosquito
cells in MEM supplemented with 10% heat-inactivated fetal bovine
serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.1 mM non-
essential amino acids, and 1 mM sodium pyruvate. Virus titer in the
culture supernatant was determined by plaque assay on Vero cells as
previously described (Rodrigo et al., 2006).
Production and characterization of human monoclonal antibodies to
dengue viruses
Humanmonoclonal antibodies against DENVwere generated from
peripheral blood mononuclear cells (PBMCs) obtained from a
convalescent dengue fever patient who had given written informed
consent and then cryopreserved. On the day of use, PBMCs were
thawed and IgG+ memory B cells were isolated from PBMC and
immortalized with EBV and CpG in multiple replicate wells as
previously described (Traggiai et al., 2004). The procedures of
screening, isolation, and functional characterization of the entire
antibody panel are detailed elsewhere (Beltramello et al., 2010). Four
of the antibodies (DVC21.8, DVC1.6, DVC23.13, and DVC35.3) were
chosen for the current study, and the characteristics of these
antibodies were described in the Results section.
Direct and ADE infection of human peripheral mononuclear cells with
dengue virus
Themethods used are essentially the same aswe previously described
(Blackley et al., 2007; Kou et al., 2008). Brieﬂy, blood was obtained from
healthy laboratory or clinicalworkerswho gave signed informed consent;
PBMCs were isolated from blood using standard density centrifugation
procedures with Ficoll-PaqueTM PLUS (Amersham Biosciences AB) and
used immediately after isolation. Federal and state rules and regulations
for protecting human research subjectswere strictly followed throughout
the course of the study. In addition, LeukoPacks were obtained from
anonymoushealthyblooddonors through theNewYorkBloodCenter and
used for isolation of PBMCs. The dengue infection status of each blood
donor was screened as previously described (Kou et al., 2008) and only
samples from dengue-naïve subjects were used.
PBMCs were infected in suspension at 2×106 cells/ml in RPMI-1640
medium supplemented with 2% heat-inactivated fetal bovine serum,
100 U/ml penicillin, 100 μg/ml streptomycin, and 2.0 mML-glutamine
(RPMI-2). For direct infection, PBMCswere incubatedwithDENV2-16681
at a multiplicity of infection (MOI) of 5, for 90 minutes at 37 °C. For ADE
infection, pooled human sera (PHS) were prepared by mixing equal
amounts of serum obtained from three dengue-immune subjects whose
sera had neutralizing reactivity to all four DENV serotypes (Rodrigo et al.,
2006). The PHSwereﬁltered through a 0.2 μmﬁlter, aliquoted, and stored
at−80 °C. DENV–immune complexes were prepared bymixing a known
amount of virus with PHS at either 1/104 or 1/105 dilutions, which
facilitate peak ADE infection as characterized in our previous studies
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used to infect PBMCs at an MOI of 5, for 90 minutes at 37 °C. For mock
infection, an equal volume of RPMI-2 was added to cells. After the
90 minute absorption, infected cells were washed twice in RPMI-2,
resuspended in RPMI-10, and cultured at 37 °C for various times at
which supernatant and cells were harvested. Cells were enumerated
using a hemacytometer and then used for ﬂow cytometry and
immunoﬂuorescence assays. Supernatants were analyzed by plaque
assay, Cytometric Bead Array (CBA) assay, and interferon bioassay.
Quantiﬁcation of infectious virus
Virus production by infected human PBMCs was quantiﬁed by an
immune focus assay with Vero cells as described (Rodrigo et al.,
2006). Brieﬂy, cell monolayers were prepared by seeding (2–3)×104/
well of Vero cells on 96-well plates overnight at 37 °C. Monolayers
were washed with PBS and incubated with supernatants harvested
from infected-PBMC at ten-fold serial dilutions for 90 minutes at
37 °C. Supernatants were removed and DMEM-2 containing 1%
methylcellulose was added. Three days later, the methylcellulose
plugs were removed, and cells were ﬁxed with 1:1 (vol./vol.) ice cold
acetone–methanol mixture. Dengue virus foci were developed with
anti-dengue envelope protein (7E1) monoclonal antibody (Rodrigo
et al., 2006) and a nickel–horseradish peroxidase-based detection kit
(Vectastain ABC kit, Vector Laboratories, Burlingame, CA). Foci were
counted using an Immunospot® analyzer (Cellular Technology Ltd,
Cleveland, OH).
Cytometric Bead Array™ (CBA) assay for cytokine levels
To determine the amounts of cytokine produced, a CBA assay
(BDBiosciences) that detects IL-1β, IL-6, IL-8, IL-10, IL-12p75, and TNF-α
in a single sample was used. Supernatant from dengue-infected PBMCs
was incubated with a mixture of speciﬁc capture antibodies that were
coupled to beads containing speciﬁc amounts of phycoerythrin (PE)
ﬂuorescence intensity. The six different ﬂuorescence intensities of PE
were detected byﬂow cytometry (FACS), and cytokine concentrations in
the samples were quantiﬁed from a standard curve according to
manufacturer's protocol. The limits of detection for these cytokines are
7.2 pg/ml (IL-1β), 2.5 pg/ml (IL-6), 3.6 pg/ml (IL-8), 3.3 pg/ml (IL-10),
1.9 pg/ml (IL-12p75), and 3.7 pg/ml (TNF-α).
Type I interferon bioassay
To assess type I interferon activity, a bioassay was performed using a
recombinant vesicular stomatitis virus (VSV) expressing a green
ﬂuorescence protein (VSV–GFP) (kindly provided by Dr. Garcia-Sastre,
Mount Sinai School of Medicine, New York). Type I interferons present in
the supernatant of dengue-infected cell protect Vero cells from VSV
infection. This can be measured by ﬂow cytometry as a reduction in the
percentage of GFP positive cells. Brieﬂy, conﬂuent Vero cells were
incubated overnight with culture supernatants harvested from mock-
infected-, DENV-infected- (noAb), or ADE-infected- (with enhancing Ab)
PBMCs andused at a½dilution. VSV–GFPwas then added to the Vero cell
monolayer at an MOI of 0.005. Cells were cultured for one day and
harvested, and the percentage of GFP+VSV-infected cells that emitted
green ﬂuorescence was quantiﬁed by FACS. Results were expressed as
percentage VSV inhibition by comparing the percentage of VSV infected
cells under direct and ADE infection conditions with that of mock
infection.
Quantiﬁcation of infected cell number by FACS and immunoﬂuorescence
staining
The number of DENV-infected cells was enumerated by twomethods
as follows: FACS assay as previously described using Alexa647-labeledanti-E antibody (Kou et al., 2008) and immunoﬂuorescence microscopy.
Infected PBMCswere adhered to poly-L-lysine-coated coverslips, blocked
with PBS containing 10% human AB serum, ﬁxed with 1:1 (vol./vol.) ice
cold acetone–methanol, and then stained with mouse anti-E primary
antibody 7E1 followed by an anti-mouse IgG secondary antibody
conjugated to FITC (BD Biosciences, San Jose, CA). The coverslips were
mounted onto glass slideswithUltraCruz™mountingmediumwithDAPI
(Santa Cruz Biotechnology, Santa Cruz, CA) and visualized using a
ﬂuorescencemicroscopeconnected toamonochromeCCDdigital camera.
A minimum of 200 cells from at least 2 ﬁelds were counted, and the
average of the 2 ﬁelds was used to calculate the percentage of infected
cells.
Statistical analysis
Results were analyzed using statistical methods in GraphPad Prism
4 software (GraphPad Software, Inc., San Diego, CA). The comparisons
between groups were performed with the Mann–Whitney test and
among data groups, with one way ANOVA. A p value of less than 0.05
was considered signiﬁcant.
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